Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Biofrontera Inc (BFRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BFRI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.38
1 Year Target Price $6.38
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -76.82% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.90M USD | Price to earnings Ratio - | 1Y Target Price 6.38 |
Price to earnings Ratio - | 1Y Target Price 6.38 | ||
Volume (30-day avg) 2 | Beta 0.3 | 52 Weeks Range 0.54 - 1.54 | Updated Date 07/17/2025 |
52 Weeks Range 0.54 - 1.54 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11194729 | Price to Sales(TTM) 0.21 |
Enterprise Value 11194729 | Price to Sales(TTM) 0.21 | ||
Enterprise Value to Revenue 0.29 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 9446200 | Shares Floating 7102407 |
Shares Outstanding 9446200 | Shares Floating 7102407 | ||
Percent Insiders 13.47 | Percent Institutions 26.14 |
Upturn AI SWOT
Biofrontera Inc
Company Overview
History and Background
Biofrontera Inc. was founded in 1997 as Biofrontera AG in Leverkusen, Germany, and later established a US subsidiary. It focuses on the development and commercialization of pharmaceutical products for the treatment of skin diseases, with a primary emphasis on photodynamic therapy (PDT).
Core Business Areas
- Prescription Dermatology: Development and commercialization of prescription drugs for dermatological conditions, particularly actinic keratosis.
- Photodynamic Therapy (PDT): Provision of a photodynamic therapy system based on topical administration of proprietary drugs followed by illumination with a specific light source.
Leadership and Structure
The leadership team consists of a CEO (Erica Monaco), CFO, and other key executives. The organizational structure includes departments for research and development, clinical affairs, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Ameluz: A prescription drug for the treatment of actinic keratosis (AK) on the face and scalp, used in combination with photodynamic therapy (PDT). Competitors include topical fluorouracil (Efudex, Carac), imiquimod (Aldara, Zyclara), and ingenol mebutate (Picato). Ameluz sales data is not publicly available but it has a significant market share in PDT for AK.
- BF-Rhodoled: A topical prescription drug for the treatment of moderate to severe acne vulgaris. Specifics are not publicly available.
Market Dynamics
Industry Overview
The dermatology market is driven by aging populations, increased awareness of skin conditions, and advancements in treatment options. The photodynamic therapy (PDT) segment is growing due to its efficacy and non-invasive nature.
Positioning
Biofrontera Inc. is a specialized pharmaceutical company focused on PDT for dermatological conditions. Its competitive advantage lies in its proprietary Ameluz drug and PDT system.
Total Addressable Market (TAM)
The global actinic keratosis treatment market is estimated at several billion dollars. Biofrontera is positioned to capture a significant portion through Ameluz and other product offerings. Estimates vary, but some reports suggest a TAM close to $5 Billion
Upturn SWOT Analysis
Strengths
- Proprietary Ameluz drug
- Established PDT system
- Focus on dermatology
- Brand recognition
Weaknesses
- Limited product portfolio
- High reliance on Ameluz
- Relatively small market cap compared to competitors
Opportunities
- Expanding indications for Ameluz
- Geographic expansion (particularly in Europe)
- Strategic partnerships
- New product development
Threats
- Competition from generic drugs
- Changes in reimbursement policies
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- LEO Pharma (private)
- Galderma (private)
- Sun Pharma (SUNPHARMA.NS)
Competitive Landscape
Biofrontera faces strong competition from larger pharmaceutical companies with broader product portfolios and greater financial resources. Its competitive advantage lies in its specialization in PDT and its proprietary Ameluz drug.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been moderate, driven by increasing adoption of Ameluz.
Future Projections: Future growth is expected to be driven by new product launches, expanded indications for Ameluz, and geographic expansion. Analyst projections vary.
Recent Initiatives: Recent initiatives include efforts to expand the market for Ameluz and to develop new products.
Summary
Biofrontera Inc. is a specialized pharmaceutical company focusing on dermatological conditions, particularly photodynamic therapy. Its strength lies in its proprietary Ameluz drug, but its limited product portfolio and reliance on Ameluz are weaknesses. Future growth opportunities include expanding indications and geographic reach, while threats include competition and changes in reimbursement policies. The company is facing a competitive landscape, and it needs to innovate and expand its product line to maintain its position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings (where available)
- Company Investor Relations Website
- Third-party market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are approximate. Financial data might not be fully available.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.